159 related articles for article (PubMed ID: 38074447)
1. An extremely rare case of recurrent pleomorphic myxoidliposarcoma with response to eribulin chemotherapy - A case report.
Rao R; Rastogi S; Kashyap D; Shamim SA; Barwad A
Rare Tumors; 2023; 15():20363613231212380. PubMed ID: 38074447
[TBL] [Abstract][Full Text] [Related]
2. Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib.
Endo M; Kataoka T; Fujiwara T; Tsukushi S; Takahashi M; Kobayashi E; Yamada Y; Tanaka T; Nezu Y; Hiraga H; Wasa J; Nagano A; Nakano K; Nakayama R; Hamada T; Kawano M; Torigoe T; Sakamoto A; Asanuma K; Morii T; Machida R; Sekino Y; Fukuda H; Oda Y; Ozaki T; Tanaka K
BMC Cancer; 2023 Mar; 23(1):219. PubMed ID: 36890471
[TBL] [Abstract][Full Text] [Related]
3. Eribulin Provides a Remarkable Effect in Trabectedin-Resistant Myxoid Liposarcoma.
Tamiya H; Sabe H; Yamashita K; Imura Y; Wakamatsu T; Takenaka S
Case Rep Orthop; 2020; 2020():8873185. PubMed ID: 33274094
[TBL] [Abstract][Full Text] [Related]
4. A rare case of myxoid pleomorphic liposarcoma in an infant: A report.
Gami S; Tiwari SB; Gautam K; Sharma S; Shrivastav S; Sapkota R
Int J Surg Case Rep; 2021 Oct; 87():106365. PubMed ID: 34517205
[TBL] [Abstract][Full Text] [Related]
5. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
Gronchi A; Ferrari S; Quagliuolo V; Broto JM; Pousa AL; Grignani G; Basso U; Blay JY; Tendero O; Beveridge RD; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Donati DM; Palassini E; Palmerini E; De Sanctis R; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Casali PG
Lancet Oncol; 2017 Jun; 18(6):812-822. PubMed ID: 28499583
[TBL] [Abstract][Full Text] [Related]
6. Established and Experimental Systemic Treatment Options for Advanced Liposarcoma.
Schöffski P
Oncol Res Treat; 2022; 45(9):525-543. PubMed ID: 35609512
[TBL] [Abstract][Full Text] [Related]
7. Histopathological Features of Myxoid Pleomorphic Liposarcoma in an African Pygmy Hedgehog (
Lee EJ; Jeong KS
Vet Sci; 2022 Nov; 9(11):. PubMed ID: 36423091
[TBL] [Abstract][Full Text] [Related]
8. Myxoid pleomorphic liposarcoma-a clinicopathologic, immunohistochemical, molecular genetic and epigenetic study of 12 cases, suggesting a possible relationship with conventional pleomorphic liposarcoma.
Creytens D; Folpe AL; Koelsche C; Mentzel T; Ferdinande L; van Gorp JM; Van der Linden M; Raman L; Menten B; Fritchie K; von Deimling A; Van Dorpe J; Flucke U
Mod Pathol; 2021 Nov; 34(11):2043-2049. PubMed ID: 34168281
[TBL] [Abstract][Full Text] [Related]
9. Myxoid pleomorphic liposarcoma is distinguished from other liposarcomas by widespread loss of heterozygosity and significantly worse overall survival: a genomic and clinicopathologic study.
Dermawan JK; Hwang S; Wexler L; Tap WD; Singer S; Vanderbilt CM; Antonescu CR
Mod Pathol; 2022 Nov; 35(11):1644-1655. PubMed ID: 35672466
[TBL] [Abstract][Full Text] [Related]
10. Recurrent Pleomorphic Myxoid Liposarcoma in a Patient With Li-Fraumeni Syndrome.
Zare SY; Leivo M; Fadare O
Int J Surg Pathol; 2020 Apr; 28(2):225-228. PubMed ID: 31559875
[TBL] [Abstract][Full Text] [Related]
11. Trabectedin as second-line treatment in metastatic myxoid liposarcoma: a case report.
Pedrinaci IZ; Jurado JM; Carrillo J; Molina MC
J Med Case Rep; 2012 Dec; 6():424. PubMed ID: 23253485
[TBL] [Abstract][Full Text] [Related]
12. Myxoid pleomorphic liposarcoma.
Fadaei S; Cordier F; Ferdinande L; Van Dorpe J; Creytens D
Histol Histopathol; 2024 Feb; ():18724. PubMed ID: 38450446
[TBL] [Abstract][Full Text] [Related]
13. Long-term disease control by trabectedin in a patient with dedifferentiated liposarcoma: A case report.
Matsuda S; Tanaka K; Kawano M; Iwasaki T; Itonaga I; Tsumura H
Medicine (Baltimore); 2020 Jan; 99(2):e18689. PubMed ID: 31914068
[TBL] [Abstract][Full Text] [Related]
14. Complete remission of a reccurrent mesenteric liposarcoma with rare histological features following the administration of trabectedin.
Tsoukalas N; Tolia M; Lypas G; Panopoulos C; Barbounis V; Koumakis G; Efremidis A
Oncol Lett; 2014 Jan; 7(1):47-49. PubMed ID: 24348818
[TBL] [Abstract][Full Text] [Related]
15. Extensive adipocytic maturation can be seen in myxoid liposarcomas treated with neoadjuvant doxorubicin and ifosfamide and pre-operative radiation therapy.
Wang WL; Katz D; Araujo DM; Ravi V; Ludwig JA; Trent JC; Patel SR; Lin PP; Guadagnolo A; Lòpez-Terrada D; Dei Tos AP; Lewis VO; Lev D; Pollock RE; Zagars GK; Benjamin RS; Madewell JE; Lazar AJ
Clin Sarcoma Res; 2012 Dec; 2(1):25. PubMed ID: 23272660
[TBL] [Abstract][Full Text] [Related]
16. Myxoid Pleomorphic Liposarcoma.
Dermawan JK
Surg Pathol Clin; 2024 Mar; 17(1):25-29. PubMed ID: 38278605
[TBL] [Abstract][Full Text] [Related]
17. Myxoid liposarcoma metastatic to the thyroid gland: a case report and literature review.
Tysome JR; Sandison A; Clarke PM
J Laryngol Otol; 2006 Jun; 120(6):511-3. PubMed ID: 16563196
[TBL] [Abstract][Full Text] [Related]
18. Managing Liposarcomas: Cutting Through the Fat.
Manji GA; Schwartz GK
J Oncol Pract; 2016 Mar; 12(3):221-7. PubMed ID: 26962163
[TBL] [Abstract][Full Text] [Related]
19. [Myxoid liposarcoma and pleomorphic liposarcoma: cyto-histological correlations].
Capitanio G; Blandamura S; Barbazza R; Caldart T; Dalla Palma P
Pathologica; 1989; 81(1075):543-9. PubMed ID: 2641156
[TBL] [Abstract][Full Text] [Related]
20. Intraperitoneal dedifferentiated liposarcoma showing MDM2 amplification: case report.
Grifasi C; Calogero A; Carlomagno N; Campione S; D'Armiento FP; Renda A
World J Surg Oncol; 2013 Nov; 11():305. PubMed ID: 24279301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
